Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Phosphorylation of protocadherin proteins by the receptor tyrosine kinase RetStefanie S Schalm, Bryan A Ballif, Sean M Buchanan, et al.
Journal of Hepatology|December 1, 1996
Relation between treatment efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)K Krogsgaard, E Christensen, N Bindslev, et al.
The Journal of Biological Chemistry|December 8, 2000
Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathwayK A Martin, S S Schalm, C Richardson, et al.
Journal of Hepatology|July 1, 1994
Analysis of hepatitis C virus genotypes by a line probe assay and correlation with antibody profilesL J van Doorn, B Kleter, L Stuyver, et al.
Hepatology (Baltimore, Md.)|August 26, 1999
Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP)C Cammà, M Giunta, L Chemello, et al.
Gastroenterology|August 1, 1976
Studies of the "e" antigen in acute and chronic hepatitisJ L Smith, B L Murphy, M O Auslander, et al.
Journal of Hepatology|October 1, 1994
The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep)K Krogsgaard, N Bindslev, E Christensen, et al.
Journal of Hepatology|July 22, 1998
Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot studyD Mutimer, N Naoumov, P Honkoop, et al.
Journal of Hepatology|March 1, 2011
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis CP-Y Bochud, S Bibert, F Negro, et al.
Gastro Hep Advances|August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar CarcinomaStefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Pageof 3